Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes

(2013) Michael Horowitz et al.   ADVANCES IN THERAPY

Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes

(2013) Tanika N. Kelly   ANNALS OF INTERNAL MEDICINE

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

(2013) M. Pinget et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

(2013) Paulus Wohlfart et al.   Journal of Translational Medicine

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

(2013) Martin Lorenz et al.   REGULATORY PEPTIDES

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Year in Diabetes 2012: The Diabetes Tsunami

(2012) R. Sherwin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

(2012) Yurong Zhang et al.   PLoS One

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs

(2011) B. Hirshberg et al.   DIABETES CARE

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

(2011) M. Riddle et al.   DIABETES CARE

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Patient adherence to medication requirements for therapy of type 2 diabetes

(2011) C. J. Bailey et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus

(2011) Raktim Kumar Ghosh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Glycemic Control and Complications in Type 2 Diabetes Mellitus

(2010) Mark Stolar   AMERICAN JOURNAL OF MEDICINE

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

(2010) M. Malm-Erjefalt et al.   DRUG METABOLISM AND DISPOSITION

Tailoring treatment to the individual in type 2 diabetes practical guidance from theGlobal Partnership for Effective Diabetes Management

(2010) S. Del Prato et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

(2010) Ulrich Werner et al.   REGULATORY PEPTIDES

Unraveling the Science of Incretin Biology

(2009) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Postprandial hyperglycemia as an etiological factor in vascular failure

(2009) Koichi Node et al.   Cardiovascular Diabetology

Intensive glucose control and macrovascular outcomes in type 2 diabetes

(2009) F. M. Turnbull et al.   DIABETOLOGIA

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE